1. Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. (December 2016) Authors: Schaefer, E.; Braiteh, F.; Forster, M.; Talbot, D.; Chandler, J.; Richards, D.; Andre, V.; Estrem, S.; Pitou, C.; Tiu, R.; Brail, L.; Nikolinakos, P. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. (August 2018) Authors: Berdeja, J.; Palandri, F.; Baer, M.R.; Quick, D.; Kiladjian, J.J.; Martinelli, G.; Verma, A.; Hamid, O.; Walgren, R.; Pitou, C.; Li, P.L.; Gerds, A.T. Journal: Leukemia research Issue: Volume 71(2018) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗